The 2 analysts offering 12-month price forecasts for Protalix Biotherapeutics Inc have a median target of 2.05, with a high estimate of 3.00 and a low estimate of 1.10. The median estimate represents a +544.45% increase from the last price of 0.32.
The current consensus among 2 polled investment analysts is to Buy stock in Protalix Biotherapeutics Inc. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.03
Reporting Date Mar 12
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.